Development of a Prophylactic mRNA Vaccine for Severe Fever with Thrombocytopenia Syndrome Using HSA based LNP.

Tsenddari Ganbold, Enkhchimeg Lkhagva, Enkhtsatsral Munkhtur, Satabdi Acharya, Hyeon Jin Kim, Seong-Tschool Hong

Abstract read

In one paragraph

Article in NPJ vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Tsenddari Ganbold *Department of Biomedical Sciences and Institute for Medical Science, Jeonbuk National University Medical School, Jeonju, South Korea.

Enkhchimeg Lkhagva *Department of Biomedical Sciences and Institute for Medical Science, Jeonbuk National University Medical School, Jeonju, South Korea.

Enkhtsatsral Munkhtur *Department of Biomedical Sciences and Institute for Medical Science, Jeonbuk National University Medical School, Jeonju, South Korea.

Satabdi AcharyaDepartment of Biomedical Sciences and Institute for Medical Science, Jeonbuk National University Medical School, Jeonju, South Korea.

Hyeon Jin KimJINIS BDRD Institute, JINIS Biopharmaceuticals Inc., Wanju, Jeonbuk, South Korea.

Seong-Tschool HongDepartment of Biomedical Sciences and Institute for Medical Science, Jeonbuk National University Medical School, Jeonju, South Korea. seonghong@jbnu.ac.kr.

Funding

National Research Foundation of Korea HV22C1234.

6 · The paper itself

Abstract

Current lipid nanoparticles (LNPs) used in mRNA vaccines typically incorporate polyethylene glycol (PEG) as a stabilizing material; however, safety concerns have prompted the search for non-PEG alternatives. Severe Fever with Thrombocytopenia Syndrome (SFTS) is a life-threatening zoonotic disease with a case fatality rate of up to 30%, and its incidence is rising in East Asia, including China, South Korea, and Japan. Despite its growing public health impact, no licensed vaccine or specific antiviral therapy is available, highlighting the urgent need for vaccine development. Human serum albumin (HSA) is a promising stabilizer, yet an HSA-based LNP mRNA vaccine has not been reported. Here, we developed SFTSV HSAmvac, an HSA-LNP mRNA vaccine encoding a modified Gn protein of SFTSV. Immunization of BALB/c and C57BL/6 mice elicited robust humoral and cellular immune responses, and vaccination of IFNAR

Identifiers

PMID41741466

DOI10.1038/s41541-026-01385-0

PMCPMC13133369

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.